AI assistant
Nicox S.A. — M&A Activity 2016
Aug 10, 2016
1556_iss_2016-08-10_2b7d4c98-3335-4a13-b150-6416f1fcd3ef.pdf
M&A Activity
Open in viewerOpens in your device viewer
completes transfer Nicox Commercial of new pan-European Operations Ophthalmic to Specialty Pharmaceutical Company led by GHO Capital
August 10, 2016
Sophia Antipolis, France.
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, today announced the completion of the transfer of its European and International commercial operations and related late-stage development programs to a newly-founded, private, pan-European ophthalmic specialty pharmaceutical company. This transfer includes the affiliates Nicox Pharma (France), together with its Spanish and UK operations, Nicox GmbH (Germany), Laboratoires Nicox (France) and Nicox Farma (Italy), all commercial products and the rights (and associated agreements) to AzaSite®, AzaSite Xtra®, BromSite™ for Europe, Middle East and Africa and NCX 4240 outside of Japan and North America. No other Nicox affiliates, operations or programs are included in or affected by this transaction.
Nicox will receive a $\bigoplus$ million cash payment from GHO Capital as a result of the completion of this transaction. For further information on the transaction, please refer to Nicox's Press Release dated July 5, 2016.
About Nicox
Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an international R&D company focused on the ophthalmic market. For more information on Nicox, its products or pipeline, please visit: www.nicox.com.
Analyst coverage
Bryan, Garnier & Co Invest Securities Gilbert Dupont Stifel
Hugo Solvet Martial Descoutures Damien Choplain Max Hermann
.......................................
Paris, France Paris, France Paris, France London, UK
. . . . . . . . . . . . . .
Upcoming financial and business conferences
| September 11-13 October 5-6 November 15-16 November 18-19 November 21-23 December 13 |
Rodman & Renshaw Annual Global Investment Conference Large & Midcap Event Stifel 2016 Healthcare Conference Actionnaria Deutsches Eigenkapitalforum Guggenheim Securities 4th Annual Boston Healthcare Conference |
New York, US Paris, France New York, US Paris, France Frankfurt, Germany Boston, US |
|---|---|---|
| …………………………………………………………………………………………. | ||
| Contacts | ||
| Nicox | Gavin Spencer Executive Vice President Corporate Development Tel +33 (0)4 97 24 53 00 [email protected] |
|
| Media Relations | ||
| United Kingdom | Jonathan Birt Tel +44 7860 361 746 [email protected] |
|
| France | NewCap Nicolas Merigeau Tel +33 (0)1 44 71 94 98 [email protected] |
|
| United States | Argot Partners Eliza Schleifstein Tel +1 (917) 763-8106 [email protected] |
|
| Investor Relations | ||
| Europe | NewCap Julien Perez Valentine Brouchot Tel +33 (0)1 44 71 94 94 [email protected] |
|
| United States | Argot Partners Melissa Forst Tel +1 (212) 600-1902 [email protected] …………………………………………………………………………………………. |
|
The information contained in this document may be modified without former notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.